Tiziana Life Sciences ( (TLSA) ) has issued an update.
On February 27, 2025, Tiziana Life Sciences announced a groundbreaking study published in Nature Neuroscience, revealing that nasal administration of its anti-CD3 monoclonal antibody significantly reduced neuroinflammation and improved recovery in a preclinical model of traumatic brain injury (TBI). The study, led by Dr. Saef Izzy at Brigham and Women’s Hospital, demonstrated that the therapy induces IL-10 producing T regulatory cells, which play a crucial role in reducing chronic microglial inflammation and enhancing brain recovery. This advancement positions Tiziana’s nasal anti-CD3 therapy as a promising treatment for TBI and potentially other neuroinflammatory conditions, addressing a major unmet medical need.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, with a favorable safety profile and potential applications in neuroinflammatory and autoimmune diseases.
YTD Price Performance: 44.12%
Average Trading Volume: 751,132
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $108.4M
See more insights into TLSA stock on TipRanks’ Stock Analysis page.